COST-EFFECTIVENESS OF RITUXIMAB-BASED CHEMOTHERAPY COMBINATIONS FOR THE INTIAL THERAPY OF FOLLICULAR LYMPHOMA

被引：0
|
作者：
Shah, G. [1 ]
Winn, A. [2 ]
Kumar, A. [3 ]
Lin, P. [3 ]
Parsons, S. [3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Univ North Carolina Chapel Hill, Chapel Hill, NC USA
[3] Tufts Med Ctr, Boston, MA USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY70
引用
收藏
页码：A221 / A221
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients
    Ohno, Shinya
    Shoji, Ayako
    Hatake, Kiyohiko
    Oya, Naoko
    Igarashi, Ataru
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (10) : 1130 - 1141
  • [32] Impact onMedical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare
    Griffiths, Robert I.
    Gleeson, Michelle L.
    Mikhael, Joseph
    Danese, Mark D.
    JOURNAL OF CANCER EPIDEMIOLOGY, 2012, 2012
  • [33] Comparing The Cost-Effectiveness Of Rituximab Maintenance (MR) and Radioimmunotherapy (RIT) Consolidation Therapy Following First-Line Chemo/Immunochemotherapies For Follicular Lymphoma
    Chen, Qiushi
    Ayer, Turgay
    Rose, Adam C.
    Nastoupil, Loretta J.
    Flowers, Christopher R.
    BLOOD, 2013, 122 (21)
  • [34] Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma
    Simone Ferrero
    Luigia Monitillo
    Barbara Mantoan
    Daniela Barbero
    Elisa Genuardi
    Sara Barbiero
    Elisa Bernocco
    Daniele Caracciolo
    Marco Ruella
    Daniela Drandi
    Manuela Zanni
    Federica Renna
    Chiara Lobetti Bodoni
    Angela Gueli
    Roberto Passera
    Pellegrino Musto
    Mario Boccadoro
    Corrado Tarella
    Marco Ladetto
    Annals of Hematology, 2013, 92 : 1503 - 1511
  • [35] Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma
    Ferrero, Simone
    Monitillo, Luigia
    Mantoan, Barbara
    Barbero, Daniela
    Genuardi, Elisa
    Barbiero, Sara
    Bernocco, Elisa
    Caracciolo, Daniele
    Ruella, Marco
    Drandi, Daniela
    Zanni, Manuela
    Renna, Federica
    Bodoni, Chiara Lobetti
    Gueli, Angela
    Passera, Roberto
    Musto, Pellegrino
    Boccadoro, Mario
    Tarella, Corrado
    Ladetto, Marco
    ANNALS OF HEMATOLOGY, 2013, 92 (11) : 1503 - 1511
  • [36] PRE-EMPTIVE RITUXIMAB-BASED TREATMENT OF MOLECULAR RELAPSES IN FOLLICULAR AND MANTLE CELL LYMPHOMA
    Ferrero, S.
    Monitillo, L.
    Mantoan, B.
    Barbero, D.
    Genuardi, E.
    Bruna, R.
    Bernocco, E.
    Caracciolo, D.
    Ruella, M.
    Drandi, D.
    Zanni, M.
    Gueli, A.
    Renna, F.
    Ghione, P.
    Bodoni, C. Lobetti
    Barbiero, S.
    Musto, P.
    Boccadoro, M.
    Tarella, C.
    Ladetto, M.
    HAEMATOLOGICA, 2012, 97 : 329 - 329
  • [37] Rituximab Maintenance Therapy Until Progression After Rituximab and Chemotherapy Induction in Patients With Follicular Lymphoma
    Yared, Jean
    Kimball, Amy
    Baer, Maria R.
    Bahrain, Huzefa
    Auerbach, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (03): : 253 - 257
  • [38] COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB MAINTENANCE TREATMENT OF FOLLICULAR LYMPHOMA IN PATIENTS RESPONDING TO FIRST-LINE INMUNOCHEMOTHERAPY INDUCTION
    Castro-gomez, A. J.
    Lopez-Guillermo, A.
    Rueda, A.
    Salar, A.
    Rubio-Terres, C.
    VALUE IN HEALTH, 2011, 14 (07) : A446 - A446
  • [39] COST-EFFECTIVENESS OF OBINUTUZUMAB COMBINED WITH CHEMOTHERAPY AS INDUCTION THERAPY AND FOLLOWED BY OBINUTUZUMAB MAINTENANCE THERAPY FOR TREATMENT NAIVE PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN MAINLAND CHINA
    Gong, Q.
    Gu, H.
    Launonen, A.
    Ran, X.
    Xia, Y.
    Chen, W.
    VALUE IN HEALTH, 2022, 25 (01) : S91 - S91
  • [40] CHEMOTHERAPY: Maintenance rituximab for relapsed follicular lymphoma
    Wrench, David
    Montoto, Silvia
    NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (12) : 677 - 678
12345